Phase II Trial of High-Dose 24-Hour Continuous Intravenous 5-Fluorouracil for Advanced Non-Small Cell Lung Cancer: A Cancer and Leukemia Group B Study

Eighty-six eligible patients with non-small cell lung cancer were treated on a Phase II, CALGB study with high-dose, 24-h continuous intravenous 5-fluorouracil every 2 weeks. Objective responses were seen in 7 (8%) patients with I (1 %) complete response and 6 (7%) partial responses. The median surv...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cancer investigation 1992, Vol.10 (3), p.215-219
Hauptverfasser:	Citron, Marc L., Modeas, Caron, Propert, Kathleen, Goutsou, Maria, Green, Mark R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Carcinoma, Non-Small-Cell Lung - drug therapy Drug Evaluation Fluorouracil - administration & dosage Fluorouracil - adverse effects Humans Lung Neoplasms - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!